Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)

This study has been completed.

Study NCT00391625 Information provided by Shire Human Genetic Therapies, Inc.

First Received: October 20, 2006 Last Updated: February 6, 2012 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	December 2011
Primary Completion Date:	December 2011 (Final data collection date for primary outcome measure)

No publications provided by Shire Human Genetic Therapies, Inc.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Zimran A, Altarescu G, Philips M, Attias D, Jmoudiak M, Deeb M, Wang N, Bhirangi K, Cohn GM, Elstein D. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood. 2010 Jun 10;115(23):4651-6. Epub 2010 Mar 18.